The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound

Kursad Erinc, Mohamad H. Yamani, Randall C. Starling, Tim Crowe, Robert Hobbs, Corinne Bott-Silverman, Gustavo Rincon, James B. Young, Jingyuan Feng, Daniel J. Cook, Nicholas Smedira, E. Murat Tuzcu

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Hypertension is a potential risk factor for allograft coronary vasculopathy. We evaluated the efficacy of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists, and their combined use, on the development of coronary vasculopathy in hypertensive heart transplant recipients. Methods: Eighty-two heart transplant recipients underwent serial intravascular ultrasound (IVUS) analysis at baseline (within 1 month) and at 1 year after transplantation and were evaluated for the development of coronary vasculopathy. Patients were divided into 4 groups. Nineteen normotensive recipients received no treatment, control (Group A). Hypertensive patients were treated with either ACE inhibitors (Group B, n = 37), calcium antagonists (Group C, n = 16), or both (Group D, n = 10). Results: We found a significant reduction in IVUS indices of coronary vasculopathy in heart transplant recipients who used a combination of an ACE inhibitor and a calcium antagonist compared with recipients who used either drug alone (p < 0.05). This synergistic efficacy was independent of the baseline indices evaluated in a multivariate regression analysis model and was noted despite comparable mean arterial pressure among the 3 hypertensive groups at 1 year, thus suggesting the presence of a synergistic anti-proliferative effect beyond the anti-hypertensive efficacy. Conclusions: The combined use of an ACE inhibitor and a calcium antagonist is more effective than the individual use of either drug alone on the development of coronary vasculopathy in cardiac transplant recipients. Large randomized clinical trials are warranted to evaluate such a synergistic efficacy.

Original languageEnglish (US)
Pages (from-to)1033-1038
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume24
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Allografts
Calcium
Pharmaceutical Preparations
Antihypertensive Agents
Arterial Pressure
Multivariate Analysis
Randomized Controlled Trials
Transplantation
Regression Analysis
Hypertension
Control Groups
Transplant Recipients
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. / Erinc, Kursad; Yamani, Mohamad H.; Starling, Randall C.; Crowe, Tim; Hobbs, Robert; Bott-Silverman, Corinne; Rincon, Gustavo; Young, James B.; Feng, Jingyuan; Cook, Daniel J.; Smedira, Nicholas; Tuzcu, E. Murat.

In: Journal of Heart and Lung Transplantation, Vol. 24, No. 8, 08.2005, p. 1033-1038.

Research output: Contribution to journalArticle

Erinc, K, Yamani, MH, Starling, RC, Crowe, T, Hobbs, R, Bott-Silverman, C, Rincon, G, Young, JB, Feng, J, Cook, DJ, Smedira, N & Tuzcu, EM 2005, 'The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound', Journal of Heart and Lung Transplantation, vol. 24, no. 8, pp. 1033-1038. https://doi.org/10.1016/j.healun.2004.06.005
Erinc, Kursad ; Yamani, Mohamad H. ; Starling, Randall C. ; Crowe, Tim ; Hobbs, Robert ; Bott-Silverman, Corinne ; Rincon, Gustavo ; Young, James B. ; Feng, Jingyuan ; Cook, Daniel J. ; Smedira, Nicholas ; Tuzcu, E. Murat. / The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. In: Journal of Heart and Lung Transplantation. 2005 ; Vol. 24, No. 8. pp. 1033-1038.
@article{276e0a62d01a457a8b1496a854f8d09c,
title = "The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound",
abstract = "Background: Hypertension is a potential risk factor for allograft coronary vasculopathy. We evaluated the efficacy of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists, and their combined use, on the development of coronary vasculopathy in hypertensive heart transplant recipients. Methods: Eighty-two heart transplant recipients underwent serial intravascular ultrasound (IVUS) analysis at baseline (within 1 month) and at 1 year after transplantation and were evaluated for the development of coronary vasculopathy. Patients were divided into 4 groups. Nineteen normotensive recipients received no treatment, control (Group A). Hypertensive patients were treated with either ACE inhibitors (Group B, n = 37), calcium antagonists (Group C, n = 16), or both (Group D, n = 10). Results: We found a significant reduction in IVUS indices of coronary vasculopathy in heart transplant recipients who used a combination of an ACE inhibitor and a calcium antagonist compared with recipients who used either drug alone (p < 0.05). This synergistic efficacy was independent of the baseline indices evaluated in a multivariate regression analysis model and was noted despite comparable mean arterial pressure among the 3 hypertensive groups at 1 year, thus suggesting the presence of a synergistic anti-proliferative effect beyond the anti-hypertensive efficacy. Conclusions: The combined use of an ACE inhibitor and a calcium antagonist is more effective than the individual use of either drug alone on the development of coronary vasculopathy in cardiac transplant recipients. Large randomized clinical trials are warranted to evaluate such a synergistic efficacy.",
author = "Kursad Erinc and Yamani, {Mohamad H.} and Starling, {Randall C.} and Tim Crowe and Robert Hobbs and Corinne Bott-Silverman and Gustavo Rincon and Young, {James B.} and Jingyuan Feng and Cook, {Daniel J.} and Nicholas Smedira and Tuzcu, {E. Murat}",
year = "2005",
month = "8",
doi = "10.1016/j.healun.2004.06.005",
language = "English (US)",
volume = "24",
pages = "1033--1038",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound

AU - Erinc, Kursad

AU - Yamani, Mohamad H.

AU - Starling, Randall C.

AU - Crowe, Tim

AU - Hobbs, Robert

AU - Bott-Silverman, Corinne

AU - Rincon, Gustavo

AU - Young, James B.

AU - Feng, Jingyuan

AU - Cook, Daniel J.

AU - Smedira, Nicholas

AU - Tuzcu, E. Murat

PY - 2005/8

Y1 - 2005/8

N2 - Background: Hypertension is a potential risk factor for allograft coronary vasculopathy. We evaluated the efficacy of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists, and their combined use, on the development of coronary vasculopathy in hypertensive heart transplant recipients. Methods: Eighty-two heart transplant recipients underwent serial intravascular ultrasound (IVUS) analysis at baseline (within 1 month) and at 1 year after transplantation and were evaluated for the development of coronary vasculopathy. Patients were divided into 4 groups. Nineteen normotensive recipients received no treatment, control (Group A). Hypertensive patients were treated with either ACE inhibitors (Group B, n = 37), calcium antagonists (Group C, n = 16), or both (Group D, n = 10). Results: We found a significant reduction in IVUS indices of coronary vasculopathy in heart transplant recipients who used a combination of an ACE inhibitor and a calcium antagonist compared with recipients who used either drug alone (p < 0.05). This synergistic efficacy was independent of the baseline indices evaluated in a multivariate regression analysis model and was noted despite comparable mean arterial pressure among the 3 hypertensive groups at 1 year, thus suggesting the presence of a synergistic anti-proliferative effect beyond the anti-hypertensive efficacy. Conclusions: The combined use of an ACE inhibitor and a calcium antagonist is more effective than the individual use of either drug alone on the development of coronary vasculopathy in cardiac transplant recipients. Large randomized clinical trials are warranted to evaluate such a synergistic efficacy.

AB - Background: Hypertension is a potential risk factor for allograft coronary vasculopathy. We evaluated the efficacy of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists, and their combined use, on the development of coronary vasculopathy in hypertensive heart transplant recipients. Methods: Eighty-two heart transplant recipients underwent serial intravascular ultrasound (IVUS) analysis at baseline (within 1 month) and at 1 year after transplantation and were evaluated for the development of coronary vasculopathy. Patients were divided into 4 groups. Nineteen normotensive recipients received no treatment, control (Group A). Hypertensive patients were treated with either ACE inhibitors (Group B, n = 37), calcium antagonists (Group C, n = 16), or both (Group D, n = 10). Results: We found a significant reduction in IVUS indices of coronary vasculopathy in heart transplant recipients who used a combination of an ACE inhibitor and a calcium antagonist compared with recipients who used either drug alone (p < 0.05). This synergistic efficacy was independent of the baseline indices evaluated in a multivariate regression analysis model and was noted despite comparable mean arterial pressure among the 3 hypertensive groups at 1 year, thus suggesting the presence of a synergistic anti-proliferative effect beyond the anti-hypertensive efficacy. Conclusions: The combined use of an ACE inhibitor and a calcium antagonist is more effective than the individual use of either drug alone on the development of coronary vasculopathy in cardiac transplant recipients. Large randomized clinical trials are warranted to evaluate such a synergistic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=23744459380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744459380&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2004.06.005

DO - 10.1016/j.healun.2004.06.005

M3 - Article

C2 - 16102438

AN - SCOPUS:23744459380

VL - 24

SP - 1033

EP - 1038

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 8

ER -